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Adiponectin is the most abundant peptide secreted by adipocytes, being a key component in the interrelationship
between adiposity, insulin resistance and inflammation. Central obesity accompanied by insulin resistance is a key
factor in the development of metabolic syndrome (MS) and future macrovascular complications. Moreover, the
remarkable correlation between coronary artery disease (CAD) and alterations in glucose metabolism has raised the
likelihood that atherosclerosis and type 2 diabetes mellitus (T2DM) may share a common biological background.
We summarize here the current knowledge about the influence of adiponectin on insulin sensitivity and
endothelial function, discussing its forthcoming prospects and potential role as a therapeutic target for MS, T2DM,
and cardiovascular disease. Adiponectin is present in the circulation as a dimer, trimer or protein complex of high
molecular weight hexamers, >400 kDa. AdipoR1 and AdipoR2 are its major receptors in vivo mediating the
metabolic actions. Adiponectin stimulates phosphorylation and AMP (adenosin mono phosphate) kinase activation,
exerting direct effects on vascular endothelium, diminishing the inflammatory response to mechanical injury and
enhancing endothelium protection in cases of apolipoprotein E deficiency. Hypoadiponectinemia is consistently
associated with obesity, MS, atherosclerosis, CAD, T2DM. Lifestyle correction helps to favorably modify plasma
adiponectin levels. Low adiponectinemia in obese patients is raised via continued weight loss programs in both
diabetic and nondiabetic individuals and is also accompanied by reductions in pro-inflammatory factors. Diet
modifications, like intake of fish, omega-3 supplementation, adherence to a Mediterranean dietary pattern and
coffee consumption also increase adiponectin levels. Antidiabetic and cardiovascular pharmacological agents, like
glitazones, glimepiride, angiotensin converting enzyme inhibitors and angiotensin receptor blockers are also able to
improve adiponectin concentration. Fibric acid derivatives, like bezafibrate and fenofibrate, have been reported to
enhance adiponectin levels as well. T-cadherin, a membrane-associated adiponectin-binding protein lacking intracellular
domain seems to be a main mediator of the antiatherogenic adiponectin actions. The finding of novel pharmacologic
agents proficient to improve adiponectin plasma levels should be target of exhaustive research. Interesting future
approaches could be the development of adiponectin-targeted drugs chemically designed to induce the activaton of
its receptors and/or postreceptor signaling pathways, or the development of specific adiponectin agonists.
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The classical view of adipose tissue as just a passive reser-
voir for energy storage has radically changed. Two types
of adipose tissue are found in mammals, brown and white,
each of them with different physiological roles. Brown
adipose tissue has specialized functions in thermogenesis
through oxidation of fatty acids due to the presence of its
specific uncoupling protein (UCP1), which uncouples
thermogenic oxidative phosphorylation [1]. Instead, white
adipose tissue stores energy in the form of triglycerides
and, in situations of energy deficit such as fasting, supplies
fatty acids to the circulation.
Thus, white adipose tissue is nowadays perceived as an
important organ involved in energy homeostasis and
body weight control. Besides its function as an energy
reservoir, it plays a key role as an organ secreting nu-
merous bioactive molecules collectively called adipo-
kines or adipocytokines [2]; the first term will be used
along the present review. The number of identified adi-
pokines is permanently increasing, as well as their po-
tential clinical diagnostic and prognostic value. These
adipokines include mainly adiponectin [2-5], leptin [5],
tumor necrosis factor (TNF) alpha [6,7], osteoprotegerin
[8] interleukin 6 (IL-6) [9], resistin [10], interleukin 1 (IL-1)
[11,12], apelin [13], visfatin [14], monocyte chemotactic
protein-1 (MCP-1) [15,16], plasminogen activator inhibitor-
1 (PAI-1) [17], retinol binding protein 4 (RBP4) [18] and
several others.
The adipokines are involved in the regulation of body
fat accumulation, adipose tissue development, energy
metabolism and control of food intake, and play also a
dominant role in the pathophysiology of several meta-
bolic disorders [2-6]. Namely, an abnormal regulation in
adipokines production will facilitate a biochemical im-
balance potentially leading to the development of various
ailments and diseases, mainly obesity, insulin resistance
(IR) and atherosclerosis, among others [2,10,19]. It should
be pinpointed that not all fatty deposits behave according
to the same pathophysiological pattern [20,21]. In particu-
lar, it has been shown that visceral fat deposits are more
metabolically active than their subcutaneous homologues,
being particularly involved in the development of diseases
associated with obesity, such as the metabolic syndrome
(MS), type 2 diabetes mellitus (T2DM) and coronary
artery disease (CAD) [21].
Adiponectin is the most abundant peptide secreted by
adipocytes [3,22], being a key component in the inter-
relationship between adiposity, insulin resistance and in-
flammation [22]. Central obesity accompanied by insulin
resistance is a key factor in the development of MS and
future macrovascular complications [23]. Moreover, the
remarkable correlation between CAD and alterations in
glucose metabolism has raised the likelihood that ath-
erosclerosis and T2DM may share a common biologicalbackground [24,25]. Large-vessel atherosclerosis can pre-
cede the development of diabetes, suggesting that rather
than atherosclerosis being a complication of diabetes, both
conditions may share similar genetic and acquired charac-
teristics, a "common soil" [26].
In the present review we summarize the current know-
ledge about the influence of adiponectin on insulin sensi-
tivity and endothelial function, discussing its forthcoming
prospects and potential role as a manifold therapeutic
target for MS, diabetes, and cardiovascular disease.Genetics, structure and circulating levels
Several studies have revealed a moderate to high estimate
of heritability (30–70%) for plasma adiponectin levels,
which are influenced by the interplay of several genes
[27-30]. A meta-analysis of genome-wide association stud-
ies performed in nearly 40000 individuals in order to iden-
tify genes associated with adiponectin levels, revealed 8
loci and confirmed other 2 previously reported loci [31].
One of the main loci seems to be on chromosome 3q27,
which contains a susceptibility locus for T2DM and MS
[32]. Reduced adiponectin levels can be caused by genetic
factors, such as the single nucleotide polymorphism (SNP)
276 in the adiponectin gene itself [33].
Analyses of SNP and mutations in the adiponectin gene
have suggested a relationship between adiponectin and
glucose metabolism diseases. For instance, SNP at position
94 associates closely with T2DM, as do SNP45 and
SNP276 [34,35], and SNP rs266729 was found to be
significantly associated with higher odds of CAD [33].
Unfavorable effects of the AdipoQ 45 T/G SNP on
lipid profile and glucose metabolism have also been de-
scribed [36]. Moreover, the latter polymorphism is also
strongly correlated with CAD in T2DM subjects [37].
Interestingly, it has been suggested that primary gen-
etic lesions that lower adiponectin levels may result in
hypertension [38]; decreased circulating adiponectin
and hypertension correlated significantly with the I164T
polymorphism [39].
Adiponectin is a protein consisting of 244 aminoacids
displaying structural similarities to collagen and TNF-
alpha, and is mostly located in adipocytes. Adiponectin
was independently identified by several research groups
using different techniques, receiving different names like
ACRP30, AdipoQ and apM1 [40-42]. Adiponectin is a
protein of 30 kDa present in the circulation as a dimer,
trimer or as a protein complex of high molecular weight
(HMW) hexamers, >400 kDa, in which the oligomers
control the biological activity of the protein [43]. The
higher order structures include also low-molecular
weight (LMW) hexamers of 180 kDa. Adiponectin can
exist in plasma in its complete form or in globular frag-
ments; the first appears to be the most common form. It
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about 0.05% of all plasma proteins [22].
The normal circulating values were initially set at
5–30 μg/ml [42], albeit subsequent investigations reported
a much narrower range - 5–10 μg/ml – [44,45]. It should
be pinpointed that ethnic and gender differences are
present; values are higher in Caucasians than in Indo-Asians
[46] and in women than in men [44], albeit significant
gender differences in adiponectin concentrations were
not observed in a Sudanese population [47]. Significantly
lower values have been reported in women with gesta-
tional diabetes [48] and during menopause [49]. Concen-
trations are at lower normal limits in obese subjects [44],
and reduced in MS, both in humans [50] and in experi-
mental animal models [51].
Importantly, adiponectin values are also systematically
lower in diabetics compared to non-diabetics, no matter
to what heart failure staging class they belong [52]. An
exception to the general rule linking increased adipo-
nectin levels with a better outcome seems to be non-
ischemic cardiomyopathy, in which despite of its high
peripheral concentrations, it does not show cardiopro-
tective effects [53].
General bioactivity
Mice studies have confirmed that adiponectin receptors
AdipoR1 and AdipoR2 are its major receptors in vivo
[54,55] mediating the metabolic actions. These effects
are also dependent on specific tissues, with muscular
AdipoR1 involved in stimulating adenosin mono phos-
phate (AMP) activated protein kinase, while hepatic
AdipoR2 is involved mainly in activation of the peroxi-
some proliferator activated receptor (PPAR) gamma.
Both AdipoR1 and AdipoR2 serve as receptors for globu-
lar and full-length adiponectin and mediate also increased
fatty-acid oxidation and glucose uptake [55,56].
Adiponectin, both in its globular and HMW forms,
stimulates phosphorylation and AMP kinase activation
in skeletal muscle. Anyway, the use of full-length adipo-
nectin produced by mammalian cells suggests that the
liver and not muscle is the primary site of adiponectin
bioactivity [57]. In addition to AMP kinase activation,
adiponectin induces carboxylase acetyl-coenzyme A phos-
phorylation, glucose uptake, nitric oxide synthesis, lactate
production in myocytes, and reduced liver production of
molecules involved in gluconeogenesis. These effects seem
responsible for the lowering of glucose levels in vivo, via
glucose utilization and fatty-acid oxidation by activating
AMP-activated protein kinase [58]. T-cadherin, a membrane-
associated adiponectin-binding protein localized in vascu-
lar smooth muscle cells and endothelial cells, seems to be
the mediator of adiponectin activity [59].
In a mammalian expression system, full-length adipo-
nectin is produced and secreted both as LMW and HMWcomplexes. Interestingly, its administration to normal weight
or obese-diabetic mice results in a decreased serum glucose
[57,60]. The effect of adiponectin on the liver requires hy-
droxylation and glycosylation of residues within the col-
lagenous domain of adiponectin [61]. This finding may
explain why studies employing the globular form (lacking
the collagenous domain) or the bacterially produced full-
length form (lacking post-translational modifications in
the collagenous domain) do not affect hepatic glucose me-
tabolism or insulin sensitivity [60]. It has been shown that
only HMW adiponectin decreases after a glucose load,
suggesting that the HMW form of adiponectin is prone
to be affected more rapidly than its LMW or medium–
molecular weight counterparts. The mechanism remains
unclear; possibly explanations may include decreased
secretion of HMW adiponectin by adipocytes, augmented
clearance of HMW adiponectin from the circulation, in-
creased metabolism of HMW adiponectin, or a combin-
ation of these facts [62]. Adiponectin is very stable in vivo
compared with other adipokines, since its half-life is very
much longer, ranging from 2.5 [63] to 14 hours [64].
Another important point that should be mentioned is
that serum adiponectin is inversely related to body fat
mass and to the degree of insulin resistance. Its concen-
tration is particularly low in adults with T2DM or CAD.
It is accepted, therefore, that adiponectin ameliorates sen-
sitivity to insulin and contributes to cardiovascular protec-
tion [65-67]. Low circulating levels, particularly of the
HMW component [68,69], are also a strong risk marker
for the development of the MS.
Hypoadiponectinemia is also associated with elevated
intramyocellular and intrahepatic lipid content, as seen
in non-alcoholic fatty liver and non-alcoholic steatohepati-
tis, additional indicators of dyslipidemia not currently
included as risk factors for the MS [70-72], showing an
inverse relationship with vascular endothelial growth
factor levels in some inflammatory settings [73].
Adiponectin and insulin sensitivity
Adiponectin increases the sensitivity to insulin through
several mechanisms. AdipoR1 and AdipoR2 are trans-
membrane receptors, whose carboxyl terminal group
(C-terminal) is located outside the membrane, and the
amino terminal group (N-terminal) inside [74]. When
adiponectin attaches to its receptor it activates AMP
kinase [19,67], promoting so glucose uptake by muscles
via intracellular translocation of the GLUT4 transporters.
Simultaneously, it hampers gluconeogenesis by inhibiting
the hepatic enzyme phosphoenolpyruvate carboxylase,
inhibits the synthesis of fatty acids and stimulates their
oxidation [22,67].
Independently, adiponectin acts as an agonist of the per-
oxisome proliferator activated receptor (PPAR) gamma
leading to additional uptake of plasmatic glucose [67].
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a good indicator for an increased risk of future develop-
ment of T2DM and MS [75]. Finally, adiponectin en-
hances insulin sensitivity by increasing hepatic insulin
receptor substrate 2 (IRS-2) expression via a macrophage-
derived IL-6-dependent pathway [66]. Thus, these mul-
tiple pathways confer to adiponectin a key role in ensuring
an effective protection against the development of insulin
resistance (IR).
Adiponectin and endothelial function
It has been shown that adiponectin exerts direct effects
on vascular endothelium, diminishing the inflammatory
response to mechanical injury and enhancing endothe-
lium protection in cases of apolipoprotein E deficiency
[43,76,77]. Regarding other lipids, cross-sectional studies
showed, after adjusting for gender and adiposity, that
adiponectin levels present a inverse correlation with
triglycerides [78], while they are directly correlated with
HDL-cholesterol [79].
It has been found that adiponectin plasma concentra-
tions are lower in individuals with CAD compared to
age- and obesity-matched controls [80] and that individ-
uals with adiponectin levels under 4 μg/ml were at in-
creased risk of CAD and presented more factors for MS
[81]. Conversely, while prospectively evaluating men
without CAD, it was found after a 6 year-follow up that
individuals in the highest percentile of plasma adiponec-
tin were at a lower risk of MI, compared with those
in the lowest percentile [82]. Adiponectin levels are
also decreased in people with hypertension, regardless
the presence of insulin resistance [83]. These subjects
are characterized by a decreased endothelium-dependent
vasodilation, which could be one of the mechanisms in-
volved in central obesity-associated hypertension [84].
It is well established that adiponectin has an antiathero-
sclerotic effect via inhibition of adhesion molecules
production, such as vascular cell adhesion protein 1
(VCAM-1) and selectin E [85,86]. The adiponectin-
mediated suppression of nuclear factor kB, could be an
important molecular mechanism for inhibiting monocytes
adhesion to endothelial cells [86]. Immunohistochemistry
studies show that adiponectin is not incorporated into the
normal and intact vessel wall, while it presents a marked
adherence to previously damaged vessel walls, like those
mechanically injured by balloon catheters [87], and adipo-
nectin may also act as a modulator for macrophage-to-
foam cell transformation, slowing or inhibiting the process
[88]. Moreover, experimental and clinical investigations
indicate that adiponectin promotes endothelial repair and
angiogenesis by increasing the number and function of
endothelial progenitor cells (EPCs) [89-91]. This EPCs-
mediated endothelial repair involves several stages, be-
ginning with mobilization of EPCs from bone marrowor spleen into the bloodstream, followed by recruit-
ment and adhesion of EPCs to the injured blood vessel
wall, and finally, differentiation and tubule formation.
Thus, adiponectin modulates almost every step of endo-
thelial repair via EPCs [92,93]. A schematic representation
of the multiple detrimental biological and clinical effects
of hypoadiponectinemia is depicted in Figure 1.
Current and forthcoming therapeutic prospects
Adiponectin levels may be negatively influenced by life-
style, such as sedentarism, a high-fat diet causing obesity,
or excessive smoking [94]. This influence can be reversed;
lifestyle correction helps to favorably modify plasma adi-
ponectin levels. Low adiponectinemia in obese patients
was raised via continued weight loss programs in both dia-
betic and nondiabetic individuals [95,96], in obese adoles-
cents [97] and was also accompanied by reductions in
pro-inflammatory factors like IL-6, leptin and TNF alpha
[98]. Moreover, increased adiponectin levels were already
apparent after 1 week (two to three bouts) of moderately
intense aerobic exercise, in some cases up to 260% [99].
Regarding diet modifications, several studies reported that
daily intake of fish or omega-3 supplementation increased
adiponectin levels by amounts ranging from 14 to 60%
[100]. Furthermore, adherence to a Mediterranean dietary
pattern showed excellent results in T2DM women [101].
Coffee consumption has also shown beneficial effects on
adiponectin levels [102].
Unfortunately, adiponectin itself cannot be adminis-
tered orally since its main component is a protein which
is dissolved by the digestive system enzymes, being thus
unable to reach the bloodstream. On the other hand,
adiponectin levels may be pharmacologically modified.
In this context, it has been found that antidiabetic treat-
ment with either insulin or metformin in experimental
models - albeit not able to improve adiponectin induced
vasodilation and endothelial function - inhibits both the
development of hypoadiponectinemia and the downregu-
lation of the adaptor protein APPL1 in mesenteric resist-
ance arteries [103]. Moreover, adiponectin concentrations
increase after pioglitazone therapy in subjects with im-
paired glucose tolerance; glitazones also improve adipo-
nectin levels in normal, obese, and T2DM subjects [104].
It should be highlighted that baseline adiponectin levels
do not predict the response to glitazones [105]. Anyway,
the use of glitazones to increase adiponectin is discour-
aged due to the potential adverse cardiovascular effects of
these drugs, like heart failure or stroke [106], especially in
the case of rosiglitazone [107]. The sulfonylurea glimepir-
ide yields also positive effects on adiponectin, particularly
in elderly T2DM patients [108].
Bezafibrate, a fibric acid derivative known for its capabil-
ity to attenuate the progression of IR in CAD patients
[109] and the declining of beta cells function in T2DM
Figure 1 Schematic depiction of the clinical outcomes of hypoadiponectinemia. Hypoadiponectinemia leads to diminished adiponectin
receptors activation accompanied by increased endothelial alterations. These factors put forth several biochemical chain reactions exerting
detrimental consequences via multiple pathways. These chain reactions may act reciprocally, finally conducting to serious cardiometabolic
derangement.
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partly acting through PPAR alpha stimulation [111]. Simi-
lar properties were reported for fenofibrate [111,112].
Cardiovascular drugs, as renin-angiotensin system block-
ing agents and angiotensin converting enzyme inhibitors
significantly increase adiponectin levels and improve insu-
lin sensitivity without affecting the degree of body adipos-
ity [113-115]. For instance, telmisartan upregulates the
expression of myocardial adiponectin, its receptor adi-
poR2, as well as GLUT4. Simultaneously, it also induces a
protective role on the vascular system by upregulating the
expression of adipoR1 and downregulating the expression
of MCP-1 and nuclear factor kappa B (NF-κB) in the ab-
dominal aorta in experimental animal models [116]. Co-
administration of candesartan and pioglitazone during
6 months to hypertensive patients with T2DM signifi-
cantly improved the baseline values of HMW adiponectin
[117]. A potential mechanism for renin angiotensin sys-
tem blocking agents to affect adiponectin levels seems to
be promotion of adipogenic differentiation of preadipo-
cytes [118] via PPAR gamma activity [119].
Attempts to increase adiponectin were also performed
with nutraceutical agents like the herb derivatives astraga-
loside II and isoastragaloside, with satisfactory results in
rodents [120,121]. In contrast, the use of purified allicin
(the active ingredient in garlic) was unsuccessful [122].
With the increasing prevalence of T2DM and obesity,
new technologies are developed to more easily monitor
adiponectin levels or its potential surrogates. Currently,
the concentration of total adiponectin maybe obtainedby a using a commercially available human adiponectin
radioimmunoassay kit [123] or enzyme-linked immuno-
sorbent assays [124]. It has been shown that salivary pH
is directly and significantly correlated to plasma adiponec-
tin levels in premenopausal and menopausal women [125].
Should this condition be confirmed for other populations,
salivary pH determination could represent an additional
noninvasive, simple, and inexpensive surrogate for adipo-
nectin assessment [126,127]. Urinary adiponectin can also
be measured, and an increased concentration is associated
with microalbuminuria and boteh micro- and macrovascu-
lar complications [128]. Anyway, laboratory methods for
adiponectin measurement still require a more appropriate
standardization, and this is also applicable to the deter-
mination of ideally therapeutic adiponectin levels for
given clinical settings. It should be mentioned that ex-
cessively high concentrations may be undesirable; it has
been reported that increased serum adiponectin and
HOMA-IR could be associated with an augmented risk
for the presence and development of cardiac autonomic
neuropathy [129].
Conclusions
As highlighted above, both functional and genetic stud-
ies on adiponectin strongly depict it as a key adipokine.
Reduced adiponectin levels seem to be not just a mere
biomarker of ailment, but play a causal role in the devel-
opment of IR, MS, T2DM, hypertension, dyslipidemia
and atherosclerosis [33,130]. On the other hand, favor-
able effects of a given adipokine on either diabetes or
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Hence, taking into consideration the high world preva-
lence of obesity, MS, T2DM and CAD, the possibility of
a defined and unique therapeutic target to simultan-
eously combat their development becomes increasingly
important [95].
Since adiponectin levels are consistently inversely corre-
lated with each of these ailments, the finding of pharma-
cologic agents proficient to improve its plasma levels
should be target of exhaustive research. An interesting ap-
proach could be the development of adiponectin-targeted
drugs chemically designed to induce the activaton of its
receptors and/or postreceptor signaling pathways. Such a
move may also be able to reverse “adiponectin resistance”,
which has been observed in both experimental and human
research models [121,132]. Moreover, orally active Adi-
poR1 and AdipoR2 agonists were already satisfactorily
used in rodent models [133]. T-cadherin, a membrane-
associated adiponectin-binding protein lacking intracellu-
lar domain [134,135] seems to be a main mediator of the
antiatherogenic adiponectin actions, and maybe a compo-
nent of insulin granules [136]. Both adiponectin and
T-cadherin were found to be inversely associated with
human aortic and coronary atherosclerosis [59], and it
appears that a majority of the whole body adiponectin
is conveyed to cardiovascular tissues by T-cadherin
[134,137,138]. T-cadherin seems to be a clue novel signal-
ing pathway at the crossroads of vascular and metabolic
disorders [139,140]. Hence, adiponectin represents in fact
a multilayered therapeutic target for MS, diabetes and
CAD. Investigating the intimate biochemical relationship
between adiponectin, its receptors AdipoR1 and AdipoR2,
and T-cadherin within the cardiovascular system could be
a very promising avenue for the development of specific
adiponectin agonists.
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